Skip to main content

Table 1 Baseline Clinical Characteristics

From: Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab

Baseline Clinical Characteristics, Mean (SD)FUNCTION Biomarker Population(n = 458)LITHE Biomarker Population(n = 287)P Value*FUNCTION ITT PopulationLITHE ITT Population
TCZ 8 mg/kg Monotherapy(n = 292)TCZ 8 mg/kg + MTX(n = 290)PBO + MTX(n = 287)TCZ 8 mg/kg + MTX(n = 398)PBO + MTX(n = 393)
Disease duration, years0.45 (0.50)8.65 (7.80)< 0.00010.5 (0.48)0.5 (0.53)0.4 (0.48)9.3 (8.2)9.0 (8.1)
TJC6828.8 (16.9)29.0 (15.5)0.559428.7 (16.3)28.7 (16.7)27.4 (16.5)29.3 (15.2)27.9 (14.8)
SJC6617.3 (11.5)16.4 (9.5)0.488916.5 (10.1)17.6 (12.4)16.2 (10.4)17.3 (9.5)16.6 (9.2)
DAS28-ESR6.7 (1.0)6.5 (0.9)0.00136.7 (1.0)6.7 (1.1)6.6 (1.0)6.6 (1.0)6.5 (1.0)
ESR, mm/h53.0 (28.8)43.1 (21.4)< 0.000151.3 (28.4)52.8 (30.2)50.4 (26.8)46.3 (24.8)46.4 (24.7)
CRP, mg/dL2.5 (2.8)2.1 (2.5)0.27022.5 (3.2)2.6 (3.0)2.3 (2.7)2.3 (2.6)2.2 (2.5)
PGA, 100-mm VAS63.0 (18.8)62.6 (16.9)0.780763.9 (18.1)63.6 (18.1)62.7 (17.3)62.7 (16.9)63.1 (17.3)
  1. CRP C-reactive protein, DAS28-ESR Disease Activity Score in 28 joints calculated with erythrocyte sedimentation rate; DMARD-IR inadequate response to disease-modifying antirheumatic drugs; ESR erythrocyte sedimentation rate; ITT intent to treat; PGA Patient Global Assessment; RA rheumatoid arthritis; SJC66 swollen joint count in 66 joints; TJC68 tender joint count in 68 joints; VAS visual analog scale
  2. * P value is for the comparison between the FUNCTION biomarker population and the LITHE biomarker population